Publicaciones en las que colabora con CAROLINA MUGURUZA MILLAN (18)

2022

  1. Glucocorticoid receptor dysregulation underlies 5-HT2AR-dependent synaptic and behavioral deficits in a mouse neurodevelopmental disorder model

    Journal of Biological Chemistry, Vol. 298, Núm. 11

2021

  1. Differential brain ADRA2A and ADRA2C gene expression and epigenetic regulation in schizophrenia. Effect of antipsychotic drug treatment

    Translational Psychiatry, Vol. 11, Núm. 1

  2. Opposite alterations of 5­HT2A receptor brain density in subjects with schizophrenia: relevance of radiotracers pharmacological profile

    Translational Psychiatry, Vol. 11, Núm. 1

  3. α2A- and α2C-adrenoceptor expression and functionality in postmortem prefrontal cortex of schizophrenia subjects

    European Neuropsychopharmacology, Vol. 52, pp. 3-11

2019

  1. Endocannabinoid system imbalance in the postmortem prefrontal cortex of subjects with schizophrenia

    Journal of Psychopharmacology, Vol. 33, Núm. 9, pp. 1132-1140

  2. Serotonin 5-HT2A receptor expression and functionality in postmortem frontal cortex of subjects with schizophrenia: Selective biased agonism via Gαi1-proteins

    European Neuropsychopharmacology, Vol. 29, Núm. 12, pp. 1453-1463

2018

  1. Disfunción sináptica y alteraciones cognitivas inducidas por los antipsicóticos

    Mente y cerebro, Núm. 90, pp. 41-43

2017

  1. Antipsychotic-induced Hdac2 transcription via NF-ΰ B leads to synaptic and cognitive side effects

    Nature Neuroscience, Vol. 20, Núm. 9, pp. 1247-1259

2016

  1. Group II metabotropic glutamate receptors as targets for novel antipsychotic drugs

    Frontiers in Pharmacology, Vol. 7, Núm. MAY

2015

  1. Erratum: α2-adrenoceptor antagonists: Synthesis, pharmacological evaluation, and molecular modeling investigation of pyridinoguanidine, pyridino-2-aminoimidazoline and their derivatives (Journal of Medicinal Chemistry (2015) 58 (963-977) DOI: 10.1021/jm501635e)

    Journal of Medicinal Chemistry

  2. α2-adrenoceptor antagonists: Synthesis, pharmacological evaluation, and molecular modeling investigation of pyridinoguanidine, pyridino-2-aminoimidazoline and their derivatives

    Journal of Medicinal Chemistry, Vol. 58, Núm. 2, pp. 963-977

2014

  1. Diferentes propiedades farmacológicas de ketanserina y altanserina sobre los receptores 5-HT2A en cerebro humano postmortem: Interés en estudio de esquizofrenia

    Actualidad en farmacología y terapéutica, Vol. 12, Núm. 1, pp. 59-63

  2. Evaluation of 5-HT2A and mGlu2/3 receptors in postmortem prefrontal cortex of subjects with major depressive disorder: Effect of antidepressant treatment

    Neuropharmacology, Vol. 86, pp. 311-318

2013

  1. Antidepressant-like properties of three new α2-adrenoceptor antagonists

    Neuropharmacology, Vol. 65, pp. 13-19

  2. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects

    European Neuropsychopharmacology, Vol. 23, Núm. 8, pp. 852-864

  3. Quantification of endocannabinoids in postmortem brain of schizophrenic subjects

    Schizophrenia Research, Vol. 148, Núm. 1-3, pp. 145-150

2012

  1. Identification of three residues essential for 5-hydroxytryptamine 2A-metabotropic glutamate 2 (5-HT2A·mGlu2) receptor heteromerization and its psychoactive behavioral function

    Journal of Biological Chemistry, Vol. 287, Núm. 53, pp. 44301-44319

2009

  1. ¿Es realmente el consumo de cannabis un factor de riesgo para la esquizofrenia?

    Norte de Salud Mental, Vol. 8, Núm. 34, pp. 23-33